Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced continued progress in intermediate-scale manufacturing and process development for key precursor components of ONC010, the company's lead nanoparticle-formulated oncology candidate. The work is being conducted with Dalton Pharma Services as part of Onco's integrated chemistry, manufacturing and controls (CMC) strategy, focusing on process optimization, analytical characterization, and manufacturing reproducibility.
These activities are designed to support future GMP production, regulatory readiness, and planned first-in-human clinical development activities in Australia. The advancement of ONC010 through IND-enabling development represents a critical step toward bringing this potential treatment to patients. The company has secured an exclusive worldwide license to patented technology targeting solid tumors, and this milestone underscores its commitment to oncology innovation.
According to the press release, the CMC strategy aims to ensure that manufacturing processes are robust and scalable, which is essential for meeting regulatory requirements and enabling clinical trials. The collaboration with Dalton Pharma Services leverages their expertise in pharmaceutical development and manufacturing. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology.
For more information, visit Onco-Innovations. The full press release can be viewed at https://ibn.fm/Unt8n.
